PharmAust (ASX:PAA), a clinical-stage oncology company, has been issued another patent in Europe.
The patent covers the use of its lead drug Monepantel (MPL) as a cancer therapy with protection until 2033.
The patent, entitled 'Kinase Inhibitors for the Treatment of Cancer', claims the use aminoacetonitrile derivatives as potent kinase inhibitors for the treatment of cancer.
Aminoacetonitrile derivatives include the Elanco compound, MPL, that PharmAust has patented for cancer and is testing in clinical trials.
According to Dr Richard Hopkins, PharmAust’s CEO, “Allowance of this Method of Use patent secures PharmAust’s core intellectual property (IP) in another key world market. It joins the family of patents that have already been granted in important major markets including the US, Australia and China giving the company IP protection. We’re delighted with this outcome as it adds to the breadth and commercial value to our patent portfolio.”